Latest news with #TomMiller
The National
20-06-2025
- Sport
- The National
SFA hit back at Rangers over John Brown 'corrupt' fine row
Bomber Brown gave his opinion when there was no goal awarded, despite the ball clearly being over the line, during Rangers' last match of last season at Easter Road. Appearing on Rangers TV that day, he said: "I would say it's corrupt." Tom Miller quickly responded: "I'm not sure we can actually say that." "Well I am saying it," Brown added. "That's a disgrace and it's the worst decision I've seen in all the years I've been in football." The SFA handed out a £3,000 fine to the Ibrox club after they were found to be in breach of the rules following the incident. Rangers issued a strongly worded statement on Thursday evening in response, as they insisted they would be watching proceedings closely relating to content produced by club TV channels of other Scottish clubs. Now, the SFA has maintained the charge was rightly passed down in line with the rulebook, as they reminded clubs of 'their responsibilities' "We note Rangers' response to the determination of a recent independent Judicial Panel Tribunal," an SFA spokesperson said. "In the interests of accuracy, we wish to address some of the misleading comments contained therein: "The sanction imposed by an independent panel was entirely in keeping with the application of the rules. "The most recent and relevant example of a similar breach, the sanction imposed on Richard Foster of Motherwell FC for comments of a similar nature in the media, attests to that. Read more: "Furthermore, to address the comments regarding 'rationale behind differing outcomes', we wish to point to the fact that investigations were undertaken in previous cases outlined and that the Compliance Officers of the time saw fit to issue a censure by way of warning letter for potential breaches deemed insufficiently serious to be progressed to a Notice of Complaint. "This system of proportionality has been adopted since the inception of the Judicial Panel Protocol in 2011. "Indeed, such discretion was exercised last season when the Compliance Officer wrote to the club to warn of the future conduct of players following matters involving Vaclav Cerny, Dujon Sterling and Mohamed Diomande. "We also note that Rangers intend to contact the association to seek clarity on the Judicial Panel Protocol and its application. "The club is, in fact, already represented on the JPP Working Group. "We have requested written reasons from the panel chair involved in the tribunal and in the interests of transparency, will publish in due course. "JPP Rule 38 was introduced in response to the referee strike of 2010, when match officials campaigned for greater protection after enduring sustained personal criticism from clubs and fans. "Ahead of a new season, we remind clubs of their responsibilities in this regard."
The Herald Scotland
20-06-2025
- Sport
- The Herald Scotland
SFA hit back at Rangers over John Brown 'corrupt' fine row
Appearing on Rangers TV that day, he said: "I would say it's corrupt." Tom Miller quickly responded: "I'm not sure we can actually say that." "Well I am saying it," Brown added. "That's a disgrace and it's the worst decision I've seen in all the years I've been in football." The SFA handed out a £3,000 fine to the Ibrox club after they were found to be in breach of the rules following the incident. Rangers issued a strongly worded statement on Thursday evening in response, as they insisted they would be watching proceedings closely relating to content produced by club TV channels of other Scottish clubs. Now, the SFA has maintained the charge was rightly passed down in line with the rulebook, as they reminded clubs of 'their responsibilities' "We note Rangers' response to the determination of a recent independent Judicial Panel Tribunal," an SFA spokesperson said. "In the interests of accuracy, we wish to address some of the misleading comments contained therein: "The sanction imposed by an independent panel was entirely in keeping with the application of the rules. "The most recent and relevant example of a similar breach, the sanction imposed on Richard Foster of Motherwell FC for comments of a similar nature in the media, attests to that. Read more: "Furthermore, to address the comments regarding 'rationale behind differing outcomes', we wish to point to the fact that investigations were undertaken in previous cases outlined and that the Compliance Officers of the time saw fit to issue a censure by way of warning letter for potential breaches deemed insufficiently serious to be progressed to a Notice of Complaint. "This system of proportionality has been adopted since the inception of the Judicial Panel Protocol in 2011. "Indeed, such discretion was exercised last season when the Compliance Officer wrote to the club to warn of the future conduct of players following matters involving Vaclav Cerny, Dujon Sterling and Mohamed Diomande. "We also note that Rangers intend to contact the association to seek clarity on the Judicial Panel Protocol and its application. "The club is, in fact, already represented on the JPP Working Group. "We have requested written reasons from the panel chair involved in the tribunal and in the interests of transparency, will publish in due course. "JPP Rule 38 was introduced in response to the referee strike of 2010, when match officials campaigned for greater protection after enduring sustained personal criticism from clubs and fans. "Ahead of a new season, we remind clubs of their responsibilities in this regard."
Daily Mail
15-06-2025
- Sport
- Daily Mail
RANGERS FURY: Ibrox club leap to John Brown's defence as SFA charge him over 'corrupt' comment
Rangers have accused the SFA of selectively enforcing their rules after former defender John Brown was charged by the governing body for claiming a controversial refereeing call was 'corrupt'. And they have vowed to back the 63-year-old who, while working as a club TV commentator at Easter Road on May 17, was incensed that his side were denied a goal when Rocky Bushiri scrambled to clear Nico Raskin's effort. With Rangers adamant the ball had crossed the line, Hibs went up the park and equalised in a match which ended 2-2. With neither referee Nick Walsh, his assistants or VAR Andrew Dallas able to conclude that the Belgian's effort should have stood, Brown said on air: 'I would say it is corrupt.' Commentator Tom Miller replied: 'Well, I'm not sure we can actually say that'. But Brown replied: 'Well, I am saying it'. Rangers later slammed the decision and called for the introduction of goal-line technology, but Brown has still been charged. The Ibrox club described Brown's comment as 'spontaneous' and 'emotional', and pointed out that an independent panel had also arrived at the conclusion that a goal should have been awarded. A spokesperson said: 'Rangers FC has submitted a full response to the Scottish FA's Notice of Complaint concerning a remark made during commentary of the Hibernian v Rangers match at the end of last season. The club firmly denies any breach of Scottish FA rules. 'We are surprised that a complaint has been raised at all, given the context of the comment and the Scottish FA's prior treatment of similar incidents. 'Our response highlights that the Scottish FA's own Key Match Incident Panel judged that the referee's decision on the day was incorrect, with four out of five panel members agreeing that a goal should have been awarded to Rangers. That finding helps explain the nature of a spontaneous emotional comment, delivered during a highly charged moment and immediately challenged live on air. 'Our response also sets out serious concerns about the Scottish FA's selective enforcement and inconsistency. We have highlighted multiple examples of similar or stronger remarks made elsewhere in Scottish football that have led to no charges or sanctions. 'While we remain committed to maintaining high standards, we will continue to challenge any action we consider to be unfair or disproportionate. For many supporters, this charge only adds to the wider frustration surrounding regulatory oversight in recent months when there are more serious issues in the game to tackle, including improving officiating standards for the benefit of Scottish football.' While the SFA-convened Key Match Incident panel, which is made up of individuals with experience from across the game, believed a goal should have been given, Hampden head of referees Willie Collum backed the match officials. Speaking on his VAR Review Show, he pointed to criticism of officials after they ruled out a Daizen Maeda goal against Hibs earlier in the season, when the ball was judged to have gone out of play before Alistair Johnston crossed to set up Maeda's 'goal'. 'Let's go back to two incidents this season first - Hibs vs Celtic, possible ball over the line, and Dundee United vs Hibs, possible handball before it goes into the goal,' Collum said. 'We were criticised for both of those decisions, and rightly so, because ultimately, there was no conclusive evidence. 'I know people who would look at this decision and say: 'That camera angle, for me, is conclusive'. But the reality is, that camera angle is at an angle looking in the way, there's nothing directly in line there. 'I've quoted before, in a World Cup match, there was a similar angle shown in a Japan game (against Spain in 2022) where, if you'd used that angle, you would say the ball was over the line. 'Then when you line it up directly in line, it only needs a slight part of the ball to be touching that line. 'Can the VAR and the AVAR there categorically, 100 per cent, say the ball was over the line? Not for us. 'Do I think it crossed the line? I think there's a good chance it did. 'But can I be absolutely certain of that? No. 'We've been criticised previously, we've now moved to say we'll only give a decision like that if we've got 100 per cent conclusive evidence, so the VAR and AVAR are correct to say there that they don't have that evidence.' Brown has been charged with breaching article 29.2 of the rules which reads: 'A club or recognised football body which publishes, distributes, issues, sells or authorises a third party to publish, distribute, issue or sell a match programme or any other publication or audio/visual material of any description in any media now existing or hereinafter invented, including but not limited to the Internet, social networking or micro-blogging sites, shall ensure that any such publications or audio/visual material does not contain any criticism of any match official calculated to indicate bias or incompetence on the part of such match official or to impinge upon his character.'
Yahoo
10-06-2025
- Business
- Yahoo
Iambic Named to CNBC's 2025 Disruptor 50 List
SAN DIEGO, June 10, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry. "While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human clinical trials," said Tom Miller, PhD, Iambic's co-founder and CEO. "Our industry-leading models design breakthrough molecular structures that unlock challenging targets, de-risk development by predicting human response early in discovery, and accelerate the delivery of both first-in-class and best-in-class drug candidates across multiple disease areas." Iambic's drug discovery platform integrates predictive modeling with automated experimentation, streamlining the pathway from discovery to clinical studies. Its lead oncology drug candidate went from program initiation to human trials in just two years, taking four years off the industry average, with a clinical data readout expected later this year. Independently and with partners, Iambic is advancing a pipeline of drug candidates for cancer and neurological diseases. Iambic recently announced advances to its two core AI drug discovery models. Enchant is the leading model for predicting clinical properties of potential drug molecules in humans, helping reduce the time, expense and risk of drug development. NeuralPLexer, which is used to predict the 3D structures of protein-ligand complexes, is faster and more accurate than AlphaFold3, giving researchers instant insights across protein classes and drug molecules to identify new drug candidates at unprecedented speed and scale. "We are working to redefine how medicines are discovered, developing AI and machine learning to increase efficiency by understanding the viability of new molecules before they enter pre-clinical and clinical studies, in turn reducing the time and cost of developing breakthrough treatments," said Fred Manby, PhD, Iambic's Chief Technology Officer and Co-Founder. "Further, we are lowering clinical trial risk and patient burden by using AI to predict drug behavior before human testing and demonstrating how computational models can help regulators accelerate drug approvals." The annual CNBC Disruptor 50 list showcases today's most forward-thinking and ambitious companies leading the way in innovation and industry transformation. Each submission underwent a thorough evaluation process, incorporating extensive research and analysis based on quantitative and qualitative metrics. Input from CNBC's editorial team and a diverse panel of entrepreneurial experts further informed the selection process. For the complete list of CNBC Disruptor 50 companies, visit About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on Contacts media@
Business Wire
10-06-2025
- Business
- Business Wire
Iambic Named to CNBC's 2025 Disruptor 50 List
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry. 'While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human clinical trials,' said Tom Miller, PhD, Iambic's co-founder and CEO. 'Our industry-leading models design breakthrough molecular structures that unlock challenging targets, de-risk development by predicting human response early in discovery, and accelerate the delivery of both first-in-class and best-in-class drug candidates across multiple disease areas.' Iambic's drug discovery platform integrates predictive modeling with automated experimentation, streamlining the pathway from discovery to clinical studies. Its lead oncology drug candidate went from program initiation to human trials in just two years, taking four years off the industry average, with a clinical data readout expected later this year. Independently and with partners, Iambic is advancing a pipeline of drug candidates for cancer and neurological diseases. Iambic recently announced advances to its two core AI drug discovery models. Enchant is the leading model for predicting clinical properties of potential drug molecules in humans, helping reduce the time, expense and risk of drug development. NeuralPLexer, which is used to predict the 3D structures of protein-ligand complexes, is faster and more accurate than AlphaFold3, giving researchers instant insights across protein classes and drug molecules to identify new drug candidates at unprecedented speed and scale. "We are working to redefine how medicines are discovered, developing AI and machine learning to increase efficiency by understanding the viability of new molecules before they enter pre-clinical and clinical studies, in turn reducing the time and cost of developing breakthrough treatments," said Fred Manby, PhD, Iambic's Chief Technology Officer and Co-Founder. 'Further, we are lowering clinical trial risk and patient burden by using AI to predict drug behavior before human testing and demonstrating how computational models can help regulators accelerate drug approvals.' The annual CNBC Disruptor 50 list showcases today's most forward-thinking and ambitious companies leading the way in innovation and industry transformation. Each submission underwent a thorough evaluation process, incorporating extensive research and analysis based on quantitative and qualitative metrics. Input from CNBC's editorial team and a diverse panel of entrepreneurial experts further informed the selection process. For the complete list of CNBC Disruptor 50 companies, visit About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at
